¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"oxidation reduction potential"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
À̰ÍÀ» ¿øÇϼ̽À´Ï±î?
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • compound muscle action potential
    º¹ÇÕ±Ù(À°)Ȱµ¿ÀüÀ§
  • compound nerve action potential
    º¹ÇսŰæÈ°µ¿ÀüÀ§
  • cortical evoked potential
    °ÑÁúÀ¯¹ßÀüÀ§, ÇÇÁúÀ¯¹ßÀüÀ§
  • critical membrane potential
    ÀӰ踷ÀüÀ§
  • cutaneous nerve somatosensory evoked potential
    ÇǺνŰæ¸ö°¨°¢À¯¹ßÀüÀ§
  • demarcation potential
    ºÐ°èÀüÀ§
  • denervation potential
    Å»½Å°æÀüÀ§
  • diffusion potential
    È®»êÀüÀ§
  • disease potential
    Áúº´ÀáÀç·Â
  • evoked potential
    À¯¹ßÀüÀ§
  • excitatory junctional potential
    ÈïºÐÁ¢ÇÕºÎÀüÀ§
  • excitatory postsynaptic potential
    ÈïºÐ½Ã³À½ºÀÌÈÄÀüÀ§, ÈïºÐ¿¬Á¢ÀÌÈÄÀüÀ§
  • early receptor potential
    Á¶±â¼ö¿ëüÀüÀ§, Á¶±â½Ã°¢¼¼Æ÷ÀüÀ§
  • electric potential
    Àü±âÀüÀ§, ÀüÀ§
  • electric potential gradient
    ÀüÀ§±â¿ï±â
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • potential barrier
    ÀüÀ§À庮
  • cognitive evoked potential
    ÀνÄÀ¯¹ßÀüÀ§
  • complex potential
    º¹ÇÕÀüÀ§
  • compound muscle action potential
    (¢¡muscle) º¹ÇÕ±ÙȰµ¿ÀüÀ§
  • compound nerve action potential
    (¢¡nerve) º¹ÇսŰæÈ°µ¿ÀüÀ§
  • cortical evoked potential
    °ÑÁúÀ¯¹ßÀüÀ§, ÇÇÁúÀ¯¹ßÀüÀ§
  • critical membrane potential
    ÀӰ踷ÀüÀ§
  • cutaneous nerve somatosensory evoked potential
    Ç¥ÇǽŰæ¸ö°¨°¢À¯¹ßÀüÀ§
  • demarcation potential
    ºÐ°èÀüÀ§
  • denervation potential
    Å»½Å°æÀüÀ§
  • diffusion potential
    È®»êÀüÀ§
  • disease potential
    Áúº´ÀáÀç·Â
  • potential difference
    Àü¾ÐÂ÷, ÀüÀ§Â÷
  • total potential energy difference
    ÃÑÀ§Ä¡¿¡³ÊÁöÂ÷
  • transmembrane potential difference
    ¸·ÀüÀ§Â÷ÀÌ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • Reinkes potential space
    ¶óÀÎÄÉ Àẹ°­
  • SEP, Somatosensory evoked potential
    ü¼º°¨°¢À¯¹ßÀüÀ§
  • absolute potential
    Àý´ëÀü¾Ð(¡­ï³äâ).³»°úÀý´ëÀüÀ§.
  • action potential
    Ȱµ¿ÀüÀ§(¡­ï³êÈ), Ȱµ¿Àü¾Ð(¡­ï³äâ)
  • alternating potential
    ±³·ù ÀüÀ§
  • generator potential
    ±âµ¿ÀüÀ§(ÑÃÔÑï³êÈ).
  • giant potential
    °Å´ëÀüÀ§(ËÝÓÞï³êÈ).
  • inhibitory junctional potential
    ¾ïÁ¦¼º Á¢ÇÕºÎÀü¾Ð(ïÈùêݬï³äâ).
  • inhibitory postsynaptic potential
    ¾ïÁ¦¼º ½Ã³³½ºÈÄ Àü¾Ð
  • inhibitory postsynaptic potential
    ¾ïÁ¦¼º ½Ã³³½ºÈÄÀü¾Ð.
  • inhibitory postsynaptic potential = IPSP
    ¾ïÁ¦¼º ½Ã³³½ºÈÄÀü¾Ð.
  • injury potential
    ¼Õ»ó(áßß¿)ÀüÀ§(ï³êÈ).
  • phase boundary potential
    »ó°èÀüÀ§(ßÓÍ£ ï³êÈ).
  • plateau potential
    °í¿øÀüÀ§.
  • polarizing potential
    ºÐ±ØÀü¾Ð(¡­ï³äâ).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • open reduction
    °³¹æ¼º Á¤º¹(ËÒÛ¯àõïÚÜÖ), °üÇ÷Àû Á¤º¹ °ñÀý(κúìîÜïÚÜÖÍéï¹), ~ÀÇ .
  • plaque reduction neutralization test
    ÇöóÅ© °¨¼ÒÁßÈ­½ÃÇè
  • plaque reduction test
    ÇöóÅ© °¨¼Ò½ÃÇè
  • pock reduction test
    Æø °¨¼ÒÁßÈ­½ÃÇè
  • proportional reduction
    ºñ·Ê°¨·Â(ÝïçÓÊõæ³).
  • reduction
    Á¤º¹¼ú, °¨¼Ò, Ãà¼Ò
  • reduction
    Á¤º¹, °¨¼Ò
  • reduction
    ȯ¿ø(ü½êª), °¨¼Ò.
  • reduction discharge
    ȯ¿ø¼º¹æ.
  • reduction division
    °¨¼öºÐ¿­
  • reduction division
    °¨¼öºÐ¿­(Êõâ¦ÝÂæñ).
  • reduction division
    °¨¼öºÐ¿­
  • reduction in area
    ´Ü¸é¼öÃà·ü(Ó¨Øüâ¥õêëÒ).
  • reduction of cardiac work load
    ½ÉÀÛ¾÷·®ÀÇ °æ°¨(ãýíÂåöåÖ¡­ÌîÊõ).
  • reduction of chromosome
    ¿°»öü°¨¼ö(æøßäô÷Êõâ¦).
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
  • oxidation state
    »êÈ­»óÅÂ(ß«ûùßÒ÷¾)
  • pentose oxidation cycle
    "ÆæÅ佺(¿Àź´ç,çé÷©ÓØ) »êÈ­ ȸ·Î(ß«ûùüÞÖØ)"
  • periodate oxidation
    °ú¿Á¼Ò»ê »êÈ­(ΦèªáÈ߫߫ûù)
  • pyruvate oxidation factor
    ÆÄÀÌ·çºê»ê(ß«) »êÈ­ÀÎÀÚ(ß«ûùì×í­)
  • action potential
    Ȱµ¿ÀüÀ§ (üÀÔÑï³êÈ)
  • asymmetry potential
    ºñ´ëĪ ÀüÀ§ (ÞªÓßöàï³êÈ)
  • breakdown potential
    ÆÄ±«Àü¾Ð(÷òÎÕï³äâ)
  • chemical potential
    È­ÇÐ(ûùùÊ)Æ÷ÅÙ¼³
  • diffusion potential
    È®»êÀüÀ§(üªß¤ï³êÈ)
  • distribution potential
    ºÐÆ÷ ÀüÀ§(ÝÂøÖï³êÈ)
  • Donnan potential
    µ·³­ ÀüÀ§(ï³êÈ)
  • electrochemical potential
    Àü±âÈ­ÇÐÀüÀ§(ï³Ñ¨ûùùÊï³êÈ)
  • electrode potential
    Àü±ØÀüÀ§(ï³Ð¿ï³êÈ)
  • electrokinetic potential
    °è¸éµ¿ÀüÀ§(Í£ØüÔÑï³êÈ)
  • electron transfer potential
    ÀüÀÚÀü´Þ ÀüÀ§(ï³í­îîÓ¹ï³êÈ)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
OFBM oxidation-fermentation basal medium
POF pattern of failure; position of function; premature ovarian failure; primary ovarian failure; pyruva...
AEP acute edematous pancreatitis; artificial endocrine pancreas; auditory evoked potential; average evok...
AP accessory pathway; accounts payable; acid phosphatase; acinar parenchyma; action potential; active p...
ERP early receptor potential; effective refractory period; elodoisin-related peptide; endoscopic retrogr...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 3
DRF Dose Reduction Factor
FECR Faecal Egg Count Reduction
FECRT Faecal egg count reduction test
LRD Limb reduction defects
LVRS Lung Volume Reduction Surgery
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • electric potential difference
    Àü¾Ð ÀüÀ§Â÷
  • electrical potential
    Àü±â·Â, ÀüÀ§
    1. Àü±âÀåÀ» ¸Å°³·Î ÇÏ¿© Á¤ÁöÇÑ ÀüÇÏ¿¡ ÀÛ¿ëÇÏ´Â Èû. 2. ¾î´À ÇÑ Á¡¿¡¼­ Àü±âÀû ÀÛ¿ëÀ» ¹ÌÄ¥ ¼ö ÀÖ´Â ¿¡³ÊÁöÀÇ ¾ç.
  • electrochemical potential
    Àü±â È­ÇÐ ÀüÀ§
  • electrode potential
    Àü±Ø Àü¾Ð
  • electromagnetic potential
    ÀüÀÚ ÀüÀ§
  • excitatory junctional potential
    ÈïºÐ¼º Á¢ÇպΠÀüÀ§
  • excitatory postsynaptic potential
    ÈïºÐ¼º ½Ã³³½º ÈÄ ÀüÀ§
    ¾Æ¼¼Æ¿Äݸ°À̳ª ±Û·çŸ¸ÞÀÌÆ®¿Í °°Àº ¹°Áú¿¡ Ȱ¼ºÈ­µÇ´Â ¾î¶² À̿ Åë·Î¸¦ ÅëÇØ ƯÁ¤ ÀÌ¿ÂÀÌ À¯ÀÔµÇ¾î ½Ã³À½º ÈO÷ÀÇ ¸·Àü¾ÐÀ» Å»ºÐ±Ø½Ã۰í, ±× °á°ú ¸·Àü¾ÐÀÌ ¿ªÄ¡¿¡ µµ´ÞÇÏ¿© ½Ã³À½ºÈÄ ¼¼Æ÷¿¡ Ȱµ¿ Àü¾ÐÀÌ »ý¼ºµÉ ¶§ ¿ªÄ¡¿¡ µµ´ÞÇϱ⠽±µµ·Ï ¸·Àü¾ÐÀ» Å»ºÐ±Ø½ÃŰ´Â Àü¾Ð.
  • fibrillation potential
    ¼¼µ¿ ÀüÀ§, Å»½Å°æ ÀüÀ§
  • inhibitory postsynaptic potential
    ¾ïÁ¦¼º ½Ã³³½ºÈÄ Àü¾Ð
    ¾ïÁ¦¼º ±¸½É·Î¿¡ ÀÏÁ¦È÷ Ãæµ¿ÀÌ °¡ÇØÁú ¶§ ½Ã³À½º ÈÄ ´º·Ð¿¡ ¹ßÇàÇÏ´Â ¸·ÀüÀ§ÀÇ Àϰú¼º °úºÐ±ØÀ̸ç, ÀÌ ¶§¹®¿¡ ½Å°æ ´ÜÀ§ÀÇ ¹ÝÀÀ¼ºÀÌ °¨¾àµÈ´Ù.
  • injury potential
    ¼Õ»ó ÀüÀ§
  • magnetic potential
    ÀÚ±â Æ÷ÅÙ¼È
  • normal potential
    Á¤»ó ÀüÀ§
  • oxidationreduction potential
    »êÈ­ ȯ¿ø ÀüÀ§
  • polarizing potential
    ºÐ±Ø Àü¾Ð
  • positive after potential
    ¾ç¼º ÈÄÀüÀ§
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 3
reduction nucleus A nucleus that degenerates in the cell during the changes incident to fertilization.
(05 Mar 2000)
reduction of chromosomes The process during meiosis whereby one member of each homologous pair of chromosomes is distributed to a sperm or ovum; the diploid set of chromosomes (46 in humans) is thus reduced to the haploid set in each gamete; union of the sperm and ovum then restores the diploid or somatic number in the one-cell zygote.
(05 Mar 2000)
reduction phase The stage of nuclear changes in the sexual cells during which reduction of the chromosomes takes place; it embraces the cell generations of the spermatocytes and oocytes.
Synonym: reduction phase.
(05 Mar 2000)
risk reduction Techniques used to reduce your chances of getting a certain cancer. For example: reducing your dietary fat may help prevent breast cancer.
(09 Oct 1997)
closed reduction The physical manipulation of a joint or bone externally (without making a surgical incision) to affect a joint relocation or more proper anatomic alignment of broken bone fragments. Closed reductions are often performed using intravenous analgesics, local anaesthetic nerve blocks or regional anaesthesia.
(27 Sep 1997)
closed reduction of fractures Reduction by manipulation of bone, without incision in the skin.
(05 Mar 2000)
Motulsky dye reduction test A test for glucose-6-phosphate dehydrogenase deficiency in the blood, using a mixture of brilliant cresyl blue, glucose-6-phosphate, and NADP.
(05 Mar 2000)
pregnancy reduction, multifetal Selective abortion of one or more embryos or foetuses in a multiple gestation pregnancy. The usual goal is to improve the outcome for the remaining embryos or foetuses.
(12 Dec 1998)
Schmorl's ferric-ferricyanide reduction stain <technique> A stain to test for reducing substances in tissues, including melanin, argentaffin granules, thyroid colloid, keratin, keratohyalin, and lipofuscin pigments; ferricyanide is converted into ferrocyanide which is converted to insoluble Prussian blue in the presence of ferric ions.
(05 Mar 2000)
selective reduction <obstetrics> A technique for intrauterine termination of one or more foetuses while leaving one or more foetuses undisturbed, usually in pregnancies with foetal anomalies or with multiple gestations.
(05 Mar 2000)
source emission reduction plan (SERP) A contingency plan developed to reduce emissions during an air quality emergency.
(05 Dec 1998)
nitroblue tetrazolium reduction <chemical> Nitroblue tetrazolium, a yellow dye, is taken up by phagocytosing neutrophils and reduced to insoluble formazan, which is deep blue, if the metabolic burst is normal. Reduction does not take place in chronic granulomatous disease.
(18 Nov 1997)
internal reduction The relocation of a joint or realignment of a fracture through a surgical incision. most internal reductions utilise general anaesthesia.
(27 Sep 1997)
open reduction of fractures Reduction by manipulation of bone, after incision in skin and muscle over the site of the fracture.
(05 Mar 2000)
tuberosity reduction The surgical excision of excessive fibrous or bony tissue in the area of the maxillary tuberosity prior to the construction of prosthetic appliances.
(05 Mar 2000)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 3
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 3
ÅëÇÕ°Ë»ö ¿Ï·á